ACM
HUMAW icon

Altium Capital Management’s Humacyte Inc Warrant HUMAW Stock Holding History

Altium Capital Management’s Portfolio HUMAW Stock Details HUMAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-137,500
Closed -$385K – 138
2021
Q2 		$385K Buy
+137,500
New +$365K 0.09% 123

Other funds holding HUMAW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

Altium Capital Management's HUMAW Position: Q3 2021 in Review

Altium Capital Management sold out of Humacyte Inc Warrant (HUMAW) in Q3 2021, closing a stake of 137,500 shares — an estimated $385K sold.

Altium Capital Management first reported a position in HUMAW in Q2 2021 and held it in 1 quarter. The position peaked at $385K in Q2 2021. 13 funds tracked by Wall St. Rank hold HUMAW as of Q3 2021.

  • Altium Capital Management reported no remaining Humacyte Inc Warrant position as of Q3 2021 after selling out during the quarter.
  • Altium Capital Management sold 137,500 Humacyte Inc Warrant shares in Q3 2021, an estimated $385K.
  • Altium Capital Management first reported a position in Humacyte Inc Warrant in Q2 2021 and held it in 1 quarter.
  • Altium Capital Management's Humacyte Inc Warrant position peaked at $385K in Q2 2021.
  • 13 funds tracked by Wall St. Rank held Humacyte Inc Warrant as of Q3 2021.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.